Fortress Biotech, Inc., formerly Coronado Biosciences, Inc., incorporated on June 28, 2006, is a biopharmaceutical company. The Company is involved in the development of immunotherapy agents for the treatment of autoimmune diseases and cancer. Its sole product candidate is CNDO-109. The Company is also focused on acquiring, developing and commercializing pharmaceutical and biotechnology products. It seeks to acquire and invest in drugs, technologies and operating subsidiaries with growth potential. The Company's product, CNDO-109, is a lysate (disrupted Closteroviridae (CTV)-1 cells, cell membrane fragments, cell proteins and other cellular components) that activates donor Natural Killer (NK) cells. CTV-1 is a leukemic cell line re-classified as a T-cell acute lymphocytic leukemia (ALL). The Company holds the license to develop and commercialize CNDO-109 to activate NK cells for the treatment of cancer-related and other conditions, and a non-exclusive license to certain clinical data solely for use in the Investigational new drug (IND) for CNDO-109. The Company is conducting the Phase I clinical studies of CNDO-109.
The Company's subsidiaries (referred as the Fortress Companies) include Avenue Therapeutics, Inc. (Avenue), Journey Medical Corporation (JMC), Coronado SO Co. (Coronado SO), Checkpoint Therapeutics, Inc. (Checkpoint), Mustang Bio, Inc. (Mustang), Helocyte, Inc. (Helocyte), Escala Therapeutics, Inc. (Escala), CB Securities Corporation and Cyprium, Inc. Avenue offers an intravenous (IV) formulation of tramadol hydrochloric acid (HCI) (IV Tramadol) for the treatment of moderate to moderately severe post-operative pain. Checkpoint is an immuno-oncology biopharmaceutical company, which is developing portfolio of human immuno-oncology targeted antibodies. Mustang is developing its own Chimeric Antigen Receptor T-Cells (CAR-T) for multiple cancers, including for acute myeloid leukemia (AML) and brain cancer.
JMC focuses on commercializing branded dermatology products through clinical development, licensing and acquisition. Helocyte holds the rights for two T-cell immunotherapeutic vaccines, known as Triplex and PepVax for controlling cytomegalovirus (CMV) in allogeneic hematopoietic stem cell transplant (HSCT) and solid organ transplant (SOT) recipients. Coronado SO, through an exclusive license agreement with a third party, holds the license for a Phase II, Uracil Topical Cream used in the treatment and prevention of hand-foot syndrome. Escala is developing N-acetyl-D-mannosamine monohydrate (ManNAc), for the treatment of GNE Myopathy (also known as Human Inclusion Body Myopathy (HIBM)), and other disorders.
2 Gansevoort St Fl 9
The company trades on NASDAQ exchange. The company headquarter is located in Massachusetts, MA. The company was established in the 2006.| Ticker | FBIO |
| Long Name | Fortress Biotech, Inc. |
| Short Name | Fortress Biotech |